
About IG-SBC JAPAN 2024
IG-SBC (Innovate Global Startup BootCamp Japan) is a global pitch event to discover and support global startups with innovative technologies and business models.
This year's competition was held in Japan, with more than 300 startups from Japan and abroad participating. After a rigorous judging process, MediScan's technology was selected as the champion.
AI-based diagnostic technology based on exhalation
The technology for which MediScan was evaluated is a system that non-invasively detects various diseases by using high-precision AI to analyze approximately 5,000 volatile organic compounds (VOCs) in human breath.
[Technology Features
Non-invasive: Testing methods that do not cause pain or radiation exposure
High accuracy: High accuracy in breast cancer detection
Simplicity: inspection can be completed in just a few minutes
Expandability: Promote research on the application of technology to cancer types other than breast cancer and to chronic diseases
Especially in breast cancer screening, it is expected to remove the psychological hurdles of pain and radiation exposure associated with mammography and contribute to improving the screening rate.
Comments from Koichiro Yoshino, President and Representative Director
We are very honored to be selected as the champion of the prestigious IG-SBC JAPAN 2024. Our goal is to create a world where everyone can easily detect diseases, including breast cancer, at an early stage. Our mission is to simplify medical diagnosis and save many lives.
Encouraged by this recognition, we will accelerate further technological development and business expansion to bring innovative medical diagnostic solutions to more patients."
Judges' Evaluation
After this pitch event, the judges gave high marks for "clear solutions to medical issues and social impact," "technological innovation and path to practical application," and "potential for global expansion.
Future Outlook
MediScan Inc. will leverage Mr. Yada's outstanding leadership and extensive business development experience to promote the following initiatives based on the philosophy of "changing healthcare through cutting-edge technology.
Completion of clinical trials and regulatory approval in Japan
Promote the introduction of breathalyzer breast cancer test equipment to medical institutions in Japan
Expansion into the U.S. and other global markets
Promotion of research into the application of technology to cancer types other than breast cancer and to chronic diseases
Develop a strategy for commercial use of big data based on breath data
MediScan will continue to strive for the development and dissemination of innovative medical technologies that contribute to the improvement of medical practice and patients' quality of life.
MediScan Corporation|Company Profile
| name of company | MediScan Corporation |
| Establishment | July 7, 2021 |
| Location | Ginza Aster Building, 7-2-6 Ginza, Chuo-ku, Tokyo |
| representative | Representative Director and President: Koichiro Yoshino |
| Business Overview | Research, development, manufacturing and sales of breathalyzer for early detection of breast cancer |
| uniform resouce locator | https://www.mediscan.co.jp/ |









